Thromb Haemost 1997; 77(01): 044-047
DOI: 10.1055/s-0038-1655904
Clinical Studies
Schattauer GmbH Stuttgart

Ongoing Prothrombotic State in the Portal Circulation of Cirrhotic Patients

Francesco Violi
1   The Istituto I Clinica Medico, Università “La Sapienza”, Rome, Italy
,
Domenico Ferro
1   The Istituto I Clinica Medico, Università “La Sapienza”, Rome, Italy
,
Stefania Basili
1   The Istituto I Clinica Medico, Università “La Sapienza”, Rome, Italy
,
Raffaella Lionetti
2   The II Cattedra di Gastroenterologia, Università “La Sapienza”, Rome, Italy
,
Elisabetta Rossi
1   The Istituto I Clinica Medico, Università “La Sapienza”, Rome, Italy
,
Manuela Merli
2   The II Cattedra di Gastroenterologia, Università “La Sapienza”, Rome, Italy
,
Oliviero Riggio
2   The II Cattedra di Gastroenterologia, Università “La Sapienza”, Rome, Italy
,
Mario Bezzi
3   Istituto di Radiologia, Università “La Sapienza”, Rome, Italy
,
Livio Capocaccia
2   The II Cattedra di Gastroenterologia, Università “La Sapienza”, Rome, Italy
› Author Affiliations
Further Information

Publication History

Received 25 July 1996

Accepted after revision 24 September 1996

Publication Date:
11 July 2018 (online)

Summary

Portal thrombosis may complicate the clinical course of cirrhosis, but the pathophysiologic mechanism is unclear. Aim of the study was to evaluate the behavior of clotting system and endotoxemia in portal vein and in peripheral circulation of 11 cirrhotic patients undergoing transjugular port-systemic shunt (TIPS).

Portal blood showed higher values of Fl+2 [Median (range): 2.5 (1.1-5.3) vs. 1.1 (0.6-2.1) nM, p <0.01], D-dimer [765 (184-1713) vs. 192 (64-813) ng/ml, p < 0.01] and endotoxemia [31 (16-47.2) vs. 13.7 (7.5-23.5) pg/ml, p <0.01] than peripheral circulation. In the portal vein, all but one sample had Fl+2 > 1.2 nM (upper limit of control values), all but one had D-dimer > 216 mg/dl (mean + 2 SD of controls) and 100% had values of endotoxemia > 9.6 pg/ml (upper limit of control values). Fibrinogen was lower in the portal circulation compared to peripheral circulation but the difference was not significant [85 (58-195) vs. 134 (75-244) mg/dl, p > 0.05].

Endotoxemia was directly correlated with Fl+2 (Rho = 0.92 p <0.006) and D-dimer (Rho = 0.93, p <0.005).

This study shows that an ongoing prothrombotic state is present in the portal circulation of cirrhotic patients and may play a pivotal role in the thrombotic episodes occurring in this clinical setting.

 
  • References

  • 1 Violi F, Leo R, Davi G, Praticò D, Iuliano L, Balsano F. Thrombocytopenia and thrombocytopathia in liver cirrhosis. Platelets 1992; 03: 233-239
  • 2 Violi F, Ferro D, Basili S, Quintarelli C, Saliola M, Alessandri C, Cordova C, Balsano F. Hyperfibrinolysis increases the risk of gastrointestinal hemorrhage in patients with advanced liver cirrhosis. Hepatology 1992; 15: 672-676
  • 3 Ferro D, Quintarelli C, Saliola M, Alessandri C, Basili S, Bonavita S, Violi F. Prevalence of hyperfibrinolysis in patients with liver cirrhosis. Fibrinolysis 1993; 01: 59-62
  • 4 Violi F, Ferro D, Basili S, Quintarelli C, Musca A, Cordova C, Balsano F. CALC Group. Hyperfibrinolysis resulting from clotting activation in patients with different degrees of cirrhosis. Hepatology 1993; 17: 78-83
  • 5 Violi F, Ferro D, Basili S, Saliola M, Quintarelli C, Alessandri C, Cordova C. Association between low-grade disseminated intravascular coagulation and endotoxemia in patients with liver cirrhosis. Gastroenterology 1995; 109: 531-539
  • 6 Oka K, Tanaka K. Intravascular coagulation in autopsy cases with liver disease. Thromb Haemost 1979; 42: 564-570
  • 7 Belli L, Romani F, Sansalone CV, Aseni P, Rondinara G. Portal thrombosis in cirrhotics. A retrospective analyses. Ann Surg 1986; 203: 286-291
  • 8 Witte CL, Brewer ML, Witte MH, Pond GB. Protean manifestations of pylethrombosis. A review of thirty-four patients. Ann Surg 1985; 202: 191-202
  • 9 Violi F, Ferro D, Basili S, D’Angelo A, Mazzola G, Quintarelli C, Cordova C. Relation between lupus anticoagulant and splanchnic venous thrombosis in cirrhosis of the liver. Br Med J 1994; 309: 239-240
  • 10 Violi F, Ferro D, Basili S, Levrero M, Cordova C. Venous thrombosis in hepatitis C virus liver cirrhosis. J Invest Med 1996; 43: 550-554
  • 11 Guamer C, Soriano C, Tomas A, Bulbena O, Novella MT, Balanzo J, Vilardell F, Movrelle M, Moncada S. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology 1993; 18: 1139-1143
  • 12 Lumsden AB, Henderson JM, Kutner MH. Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral blood in patients with cirrhosis. Hepatology 1988; 08: 232-236
  • 13 Van Deventer SJH, Buller HR, Ten Cate JW, Aarden LA, Hack CE, Sturk A. Experimental endotoxemia in human: analysis of cytokine release and coagulation fibrinolytic and complement pathways. Blood 1990; 12: 2520-2526
  • 14 Pugh RNH, Murray-Lyon IM, Dawson JL. Transection of oesophagus for bleeding oesophagus varices. Br J Surg 1973; 60: 646-649
  • 15 Rössle M, Haag K, Ochs A, Sellinger M, Nöldge G, Peramau JM, Berger E, Blum V, Gabelmann A, Havenstein KH, Langer M, Gerok W. The transjugular intrahepatic portosystemic stent-shunt procedure for variceal bleeding. N Engl J Med 1994; 330: 165-171
  • 16 Ochs A, Rössle M, Haag K, Hauenstein KH, Deibert P, Siegerstetter V, Huonker M, Langer M, Blum HE. The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites. N Engl J Med 1995; 332: 1192-1197
  • 17 Pelzer H, Schwartz W. Determination of human prothrombin activation fragment Fl+2 in plasma with antibody against a synthetic peptide. Thromb Haemost 1991; 65: 153-159
  • 18 Armitage P, Berry G. Statistical methods in medical research. 02. nd ed Blackwell scientific Publication; Oxford (UK): 1990: 200-215
  • 19 Bauer KA, Rosemberg RD. The pathogenesis of the prethrombotic state in humans: insights from studies using markers of hemostatic system activation. Blood 1987; 70: 343-350
  • 20 Ravin HA, Rowey D, Senkins C, Fine J. On the observation of bacterial endotoxin from the gastrointestinal tract of the normal and shocked animal. J Exp Med 1960; 112: 783-792
  • 21 Wolter J, Liehr H, Grun M. Hepatic clearance of endotoxins: differences in arterial and portal perfusion. J Ret Soc 1978; 03: 145-152
  • 22 Liehr H. Endotoxins and the pathogenesis of hepatic and gastrointestinal diseases. Adr Intern Med Pediatr 1982; 48: 117-193
  • 23 Semeraro N, Biondi A, Lorenzet R, Locati D, Mantovani A, Donati MB. Direct induction of tissue factor synthesis by endotoxin in human macrophages from diverse anatomical sites. Immunology 1983; 50: 529-535
  • 24 Colucci M, Balconi G, Lorenzet R, Pietra A, Locati PD. Cultured human endothelial cells generate tissue factor in response to endotoxin. J Clin Invest 1983; 71: 1893-1896
  • 25 Devière J, Content J, Denys C, Vandenbussche P, Schandene L, Wybran J, Dupont I. Excessive in vitro Lipopolysaccharide-induced production of monokines in cirrhosis. Hepatology 1990; 11: 628-634
  • 26 Scarpati EM, Sadler SE. Regulation of endothelial cell coagulant properties. Modulation of tissue factor, plasminogen activator inhibitors, and thrombomodulin by phorbol 12-myristate 13-acetate and tumor necrosis factor. J Biol Chem 1989; 264: 20705-20713
  • 27 Van Der Poll T, Buller HR, ten Cate H, Wortel CH, Baver KA, Van Deventer SJH, Hack CE, Saverwein HP, Rosenberg RD, Ten Cate JW. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990; 322: 1622-1627